Regulators of mammalian Hippo pathway in cancer

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1826, Issue 2, 2012, Pages 357-364

  Liu, Angela M ^a,c   Wong, Kwong Fai ^b,c   Jiang, Xiaoou ^a   Qiao, Yiting ^b   Luk, John M ^a,b,c  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c Roche RandD Center China Ltd   (China)

Author keywords

Hippo signaling; LATS1 2; MST1 2; Regulators; Solid cancer; YAP

Indexed keywords

LARGE TUMOR SUPPRESSOR 1; LARGE TUMOR SUPPRESSOR 2; MAMMALIAN STERILE 20 LIKE KINASE 1; MAMMALIAN STERILE 20 LIKE KINASE 2; MPS ONCE BINDER KINASE ACTIVATOR LIKE 1; REGULATOR PROTEIN; SALVADOR1 PROTEIN; UNCLASSIFIED DRUG; YES ASSOCIATED PROTEIN;

CANCER INHIBITION; CANCER SURVIVAL; CONFORMATIONAL TRANSITION; DOWN REGULATION; HIPPO PATHWAY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; TIGHT JUNCTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CELL CYCLE PROTEINS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

MAMMALIA;

EID: 84862683338     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2012.05.006     Document Type: Review

References (113)

1. Lobry C., Oh P., Aifantis I. Oncogenic and tumor suppressor functions of Notch in cancer: it's NOTCH what you think. J. Exp. Med. 2011, 208:1931-1935.
2. Ng J.M., Curran T. The Hedgehog's tale: developing strategies for targeting cancer. Nat. Rev. Cancer 2011, 11:493-501.
3. Yao H., Ashihara E., Maekawa T. Targeting the Wnt/beta-catenin signaling pathway in human cancers. Expert Opin. Ther. Targets 2011, 15:873-887.
4. Justice R.W., Zilian O., Woods D.F., Noll M., Bryant P.J. The Drosophila tumor suppressor gene warts encodes a homolog of human myotonic dystrophy kinase and is required for the control of cell shape and proliferation. Genes Dev. 1995, 9:534-546.
5. Tapon N., Harvey K.F., Bell D.W., Wahrer D.C., Schiripo T.A., Haber D.A., Hariharan I.K. Salvador promotes both cell cycle exit and apoptosis in Drosophila and is mutated in human cancer cell lines. Cell 2002, 110:467-478.
6. Harvey K.F., Pfleger C.M., Hariharan I.K. The Drosophila Mst ortholog, hippo, restricts growth and cell proliferation and promotes apoptosis. Cell 2003, 114:457-467.
7. Pantalacci S., Tapon N., Leopold P. The Salvador partner Hippo promotes apoptosis and cell-cycle exit in Drosophila. Nat. Cell Biol. 2003, 5:921-927.
8. Udan R.S., Kango-Singh M., Nolo R., Tao C., Halder G. Hippo promotes proliferation arrest and apoptosis in the Salvador/Warts pathway. Nat. Cell Biol. 2003, 5:914-920.
9. Wu S., Huang J., Dong J., Pan D. Hippo encodes a Ste-20 family protein kinase that restricts cell proliferation and promotes apoptosis in conjunction with salvador and warts. Cell 2003, 114:445-456.
10. Dong J., Feldmann G., Huang J., Wu S., Zhang N., Comerford S.A., Gayyed M.F., Anders R.A., Maitra A., Pan D. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell 2007, 130:1120-1133.
11. Oh H., Irvine K.D. In vivo analysis of Yorkie phosphorylation sites. Oncogene 2009, 28:1916-1927.
12. Thompson B.J., Cohen S.M. The Hippo pathway regulates the bantam microRNA to control cell proliferation and apoptosis in Drosophila. Cell 2006, 126:767-774.
13. Nolo R., Morrison C.M., Tao C., Zhang X., Halder G. The bantam microRNA is a target of the Hippo tumor-suppressor pathway. Curr. Biol. 2006, 16:1895-1904.
14. Lai Z.C., Wei X., Shimizu T., Ramos E., Rohrbaugh M., Nikolaidis N., Ho L.L., Li Y. Control of cell proliferation and apoptosis by mob as tumor suppressor, mats. Cell 2005, 120:675-685.
15. Tao W., Zhang S., Turenchalk G.S., Stewart R.A., St John M.A., Chen W., Xu T. Human homologue of the Drosophila melanogaster lats tumour suppressor modulates CDC2 activity. Nat. Genet. 1999, 21:177-181.
16. Huang J., Wu S., Barrera J., Matthews K., Pan D. The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila homolog of YAP. Cell 2005, 122:421-434.
17. Willecke M., Hamaratoglu F., Kango-Singh M., Udan R., Chen C.L., Tao C., Zhang X., Halder G. The fat cadherin acts through the hippo tumor-suppressor pathway to regulate tissue size. Curr. Biol. 2006, 16:2090-2100.
18. Cho E., Feng Y., Rauskolb C., Maitra S., Fehon R., Irvine K.D. Delineation of a Fat tumor suppressor pathway. Nat. Genet. 2006, 38:1142-1150.
19. Silva E., Tsatskis Y., Gardano L., Tapon N., McNeill H. The tumor-suppressor gene fat controls tissue growth upstream of expanded in the hippo signaling pathway. Curr. Biol. 2006, 16:2081-2089.
20. Bennett F.C., Harvey K.F. Fat cadherin modulates organ size in Drosophila via the Salvador/Warts/Hippo signaling pathway. Curr. Biol. 2006, 16:2101-2110.
21. Willecke M., Hamaratoglu F., Sansores-Garcia L., Tao C., Halder G. Boundaries of Dachsous cadherin activity modulate the Hippo signaling pathway to induce cell proliferation. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:14897-14902.
22. Tyler D.M., Baker N.E. Expanded and fat regulate growth and differentiation in the Drosophila eye through multiple signaling pathways. Dev. Biol. 2007, 305:187-201.
23. Baumgartner R., Poernbacher I., Buser N., Hafen E., Stocker H. The WW domain protein KIBRA acts upstream of Hippo in Drosophila. Dev. Cell 2010, 18:309-316.
24. Genevet A., Wehr M.C., Brain R., Thompson B.J., Tapon N. KIBRA is a regulator of the Salvador/Warts/Hippo signaling network. Dev. Cell 2010, 18:300-308.
25. Yu J., Zheng Y., Dong J., Klusza S., Deng W.M., Pan D. KIBRA functions as a tumor suppressor protein that regulates Hippo signaling in conjunction with Merlin and Expanded. Dev. Cell 2010, 18:288-299.
26. Ishiuchi T., Misaki K., Yonemura S., Takeichi M., Tanoue T. Mammalian fat and Dachsous cadherins regulate apical membrane organization in the embryonic cerebral cortex. J. Cell Biol. 2009, 185:959-967.
27. Mao Y., Mulvaney J., Zakaria S., Yu T., Morgan K.M., Allen S., Basson M.A., Francis-West P., Irvine K.D. Characterization of a Dchs1 mutant mouse reveals requirements for Dchs1-Fat4 signaling during mammalian development. Development 2011, 138:947-957.
28. Zhang N., Bai H., David K.K., Dong J., Zheng Y., Cai J., Giovannini M., Liu P., Anders R.A., Pan D. The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev. Cell 2010, 19:27-38.
29. Xiao L., Chen Y., Ji M., Dong J. KIBRA regulates Hippo signaling activity via interactions with large tumor suppressor kinases. J. Biol. Chem. 2011, 286:7788-7796.
30. Lu L., Li Y., Kim S.M., Bossuyt W., Liu P., Qiu Q., Wang Y., Halder G., Finegold M.J., Lee J.S., Johnson R.L. Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:1437-1442.
31. Zhou D., Conrad C., Xia F., Park J.S., Payer B., Yin Y., Lauwers G.Y., Thasler W., Lee J.T., Avruch J., Bardeesy N. Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell 2009, 16:425-438.
32. Zang Z.J., Cutcutache I., Poon S.L., Zhang S.L., McPherson J.R., Tao J., Rajasegaran V., Heng H.L., Deng N., Gan A., Lim K.H., Ong C.K., Huang D., Chin S.Y., Tan I.B., Ng C.C., Yu W., Wu Y., Lee M., Wu J., Poh D., Wan W.K., Rha S.Y., So J., Salto-Tellez M., Yeoh K.G., Wong W.K., Zhu Y.J., Futreal P.A., Pang B., Ruan Y., Hillmer A.M., Bertrand D., Nagarajan N., Rozen S., Teh B.T., Tan P. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat. Gent. 2012, 44:570-574.
33. Xu Z.P., Zhu J.S., Zhang Q., Wang X.Y. A breakdown of the Hippo pathway in gastric cancer. Hepatogastroenterology 2011, 58:1611-1617.
34. Zender L., Spector M.S., Xue W., Flemming P., Cordon-Cardo C., Silke J., Fan S.T., Luk J.M., Wigler M., Hannon G.J., Mu D., Lucito R., Powers S., Lowe S.W. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 2006, 125:1253-1267.
35. Xu M.Z., Yao T.J., Lee N.P., Ng I.O., Chan Y.T., Zender L., Lowe S.W., Poon R.T., Luk J.M. Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer 2009, 115:4576-4585.
36. Li H., Wolfe A., Septer S., Edwards G., Zhong X., Bashar Abdulkarim A., Ranganathan S., Apte U. Deregulation of Hippo kinase signalling in human hepatic malignancies. Liver Int. 2011.
37. Murakami H., Mizuno T., Taniguchi T., Fujii M., Ishiguro F., Fukui T., Akatsuka S., Horio Y., Hida T., Kondo Y., Toyokuni S., Osada H., Sekido Y. LATS2 is a tumor suppressor gene of malignant mesothelioma. Cancer Res. 2011, 71:873-883.
38. Seidel C., Schagdarsurengin U., Blumke K., Wurl P., Pfeifer G.P., Hauptmann S., Taubert H., Dammann R. Frequent hypermethylation of MST1 and MST2 in soft tissue sarcoma. Mol. Carcinog. 2007, 46:865-871.
39. Tschop K., Conery A.R., Litovchick L., Decaprio J.A., Settleman J., Harlow E., Dyson N. A kinase shRNA screen links LATS2 and the pRB tumor suppressor. Genes Dev. 2011, 25:814-830.
40. Radu M., Chernoff J. The DeMSTification of mammalian Ste20 kinases. Curr. Biol. 2009, 19:R421-R425.
41. Avruch J., Zhou D., Fitamant J., Bardeesy N. Mst1/2 signalling to Yap: gatekeeper for liver size and tumour development. Br. J. Cancer 2010, 104:24-32.
42. Glantschnig H., Rodan G.A., Reszka A.A. Mapping of MST1 kinase sites of phosphorylation. Activation and autophosphorylation. J. Biol. Chem. 2002, 277:42987-42996.
43. Deng Y., Pang A., Wang J.H. Regulation of mammalian STE20-like kinase 2 (MST2) by protein phosphorylation/dephosphorylation and proteolysis. J. Biol. Chem. 2003, 278:11760-11767.
44. Liu L., Tommasi S., Lee D.H., Dammann R., Pfeifer G.P. Control of microtubule stability by the RASSF1A tumor suppressor. Oncogene 2003, 22:8125-8136.
45. Song M.S., Song S.J., Ayad N.G., Chang J.S., Lee J.H., Hong H.K., Lee H., Choi N., Kim J., Kim H., Kim J.W., Choi E.J., Kirschner M.W., Lim D.S. The tumour suppressor RASSF1A regulates mitosis by inhibiting the APC-Cdc20 complex. Nat. Cell Biol. 2004, 6:129-137.
46. Polesello C., Huelsmann S., Brown N.H., Tapon N. The Drosophila RASSF homolog antagonizes the hippo pathway. Curr. Biol. 2006, 16:2459-2465.
47. Scheel H., Hofmann K. A novel interaction motif, SARAH, connects three classes of tumor suppressor. Curr. Biol. 2003, 13:R899-R900.
48. Praskova M., Khoklatchev A., Ortiz-Vega S., Avruch J. Regulation of the MST1 kinase by autophosphorylation, by the growth inhibitory proteins, RASSF1 and NORE1, and by Ras. Biochem. J. 2004, 381:453-462.
49. Oh H.J., Lee K.K., Song S.J., Jin M.S., Song M.S., Lee J.H., Im C.R., Lee J.O., Yonehara S., Lim D.S. Role of the tumor suppressor RASSF1A in Mst1-mediated apoptosis. Cancer Res. 2006, 66:2562-2569.
50. Guo C., Tommasi S., Liu L., Yee J.K., Dammann R., Pfeifer G.P. RASSF1A is part of a complex similar to the Drosophila Hippo/Salvador/Lats tumor-suppressor network. Curr. Biol. 2007, 17:700-705.
51. Guo C., Zhang X., Pfeifer G.P. The tumor suppressor RASSF1A prevents dephosphorylation of the mammalian STE20-like kinases MST1 and MST2. J. Biol. Chem. 2011, 286:6253-6261.
52. Ribeiro P.S., Josue F., Wepf A., Wehr M.C., Rinner O., Kelly G., Tapon N., Gstaiger M. Combined functional genomic and proteomic approaches identify a PP2A complex as a negative regulator of Hippo signaling. Mol. Cell 2010, 39:521-534.
53. Jang S.W., Yang S.J., Srinivasan S., Ye K. Akt phosphorylates MstI and prevents its proteolytic activation, blocking FOXO3 phosphorylation and nuclear translocation. J. Biol. Chem. 2007, 282:30836-30844.
54. Qiao M., Wang Y., Xu X., Lu J., Dong Y., Tao W., Stein J., Stein G.S., Iglehart J.D., Shi Q., Pardee A.B. Mst1 is an interacting protein that mediates PHLPPs' induced apoptosis. Mol. Cell 2010, 38:512-523.
55. Mehrotra J., Vali M., McVeigh M., Kominsky S.L., Fackler M.J., Lahti-Domenici J., Polyak K., Sacchi N., Garrett-Mayer E., Argani P., Sukumar S. Very high frequency of hypermethylated genes in breast cancer metastasis to the bone, brain, and lung. Clin. Cancer Res. 2004, 10:3104-3109.
56. Topaloglu O., Hoque M.O., Tokumaru Y., Lee J., Ratovitski E., Sidransky D., Moon C.S. Detection of promoter hypermethylation of multiple genes in the tumor and bronchoalveolar lavage of patients with lung cancer. Clin. Cancer Res. 2004, 10:2284-2288.
57. Lee S., Lee H.J., Kim J.H., Lee H.S., Jang J.J., Kang G.H. Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. Am. J. Pathol. 2003, 163:1371-1378.
58. Kang G.H., Lee S., Kim J.S., Jung H.Y. Profile of aberrant CpG island methylation along multistep gastric carcinogenesis. Lab. Invest. 2003, 83:519-526.
59. Lee S., Hwang K.S., Lee H.J., Kim J.S., Kang G.H. Aberrant CpG island hypermethylation of multiple genes in colorectal neoplasia. Lab. Invest. 2004, 84:884-893.
60. Calvisi D.F., Ladu S., Gorden A., Farina M., Conner E.A., Lee J.S., Factor V.M., Thorgeirsson S.S. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 2006, 130:1117-1128.
61. Macheiner D., Gauglhofer C., Rodgarkia-Dara C., Grusch M., Brachner A., Bichler C., Kandioler D., Sutterluty H., Mikulits W., Schulte-Hermann R., Grasl-Kraupp B. NORE1B is a putative tumor suppressor in hepatocarcinogenesis and may act via RASSF1A. Cancer Res. 2009, 69:235-242.
62. Liu J., Weiss H.L., Rychahou P., Jackson L.N., Evers B.M., Gao T. Loss of PHLPP expression in colon cancer: role in proliferation and tumorigenesis. Oncogene 2009, 28:994-1004.
63. Lee J.H., Kim T.S., Yang T.H., Koo B.K., Oh S.P., Lee K.P., Oh H.J., Lee S.H., Kong Y.Y., Kim J.M., Lim D.S. A crucial role of WW45 in developing epithelial tissues in the mouse. EMBO J. 2008, 27:1231-1242.
64. Lee K.P., Lee J.H., Kim T.S., Kim T.H., Park H.D., Byun J.S., Kim M.C., Jeong W.I., Calvisi D.F., Kim J.M., Lim D.S. The Hippo-Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:8248-8253.
65. Chan E.H., Nousiainen M., Chalamalasetty R.B., Schafer A., Nigg E.A., Sillje H.H. The Ste20-like kinase Mst2 activates the human large tumor suppressor kinase Lats1. Oncogene 2005, 24:2076-2086.
66. Donninger H., Allen N., Henson A., Pogue J., Williams A., Gordon L., Kassler S., Dunwell T., Latif F., Clark G.J. Salvador protein is a tumor suppressor effector of RASSF1A with hippo pathway-independent functions. J. Biol. Chem. 2011, 286:18483-18491.
67. Kosaka Y., Mimori K., Tanaka F., Inoue H., Watanabe M., Mori M. Clinical significance of the loss of MATS1 mRNA expression in colorectal cancer. Int. J. Oncol. 2007, 31:333-338.
68. Praskova M., Xia F., Avruch J. MOBKL1A/MOBKL1B phosphorylation by MST1 and MST2 inhibits cell proliferation. Curr. Biol. 2008, 18:311-321.
69. Bao Y., Sumita K., Kudo T., Withanage K., Nakagawa K., Ikeda M., Ohno K., Wang Y., Hata Y. Roles of mammalian sterile 20-like kinase 2-dependent phosphorylations of Mps one binder 1B in the activation of nuclear Dbf2-related kinases. Genes Cells 2009, 14:1369-1381.
70. St John M.A., Tao W., Fei X., Fukumoto R., Carcangiu M.L., Brownstein D.G., Parlow A.F., McGrath J., Xu T. Mice deficient of Lats1 develop soft-tissue sarcomas, ovarian tumours and pituitary dysfunction. Nat. Genet. 1999, 21:182-186.
71. Yabuta N., Okada N., Ito A., Hosomi T., Nishihara S., Sasayama Y., Fujimori A., Okuzaki D., Zhao H., Ikawa M., Okabe M., Nojima H. Lats2 is an essential mitotic regulator required for the coordination of cell division. J. Biol. Chem. 2007, 282:19259-19271.
72. Kawahara M., Hori T., Chonabayashi K., Oka T., Sudol M., Uchiyama T. Kpm/Lats2 is linked to chemosensitivity of leukemic cells through the stabilization of p73. Blood 2008, 112:3856-3866.
73. Yang X., Li D.M., Chen W., Xu T. Human homologue of Drosophila lats, LATS1, negatively regulate growth by inducing G(2)/M arrest or apoptosis. Oncogene 2001, 20:6516-6523.
74. Xia H., Qi H., Li Y., Pei J., Barton J., Blackstad M., Xu T., Tao W. LATS1 tumor suppressor regulates G2/M transition and apoptosis. Oncogene 2002, 21:1233-1241.
75. Hergovich A., Schmitz D., Hemmings B.A. The human tumour suppressor LATS1 is activated by human MOB1 at the membrane. Biochem. Biophys. Res. Commun. 2006, 345:50-58.
76. Yabuta N., Mukai S., Okada N., Aylon Y., Nojima H. The tumor suppressor Lats2 is pivotal in Aurora A and Aurora B signaling during mitosis. Cell Cycle 2011, 10:2724-2736.
77. Xiao L., Chen Y., Ji M., Volle D.J., Lewis R.E., Tsai M.Y., Dong J. KIBRA protein phosphorylation is regulated by mitotic kinase aurora and protein phosphatase 1. J. Biol. Chem. 2011, 286:36304-36315.
78. Paramasivam M., Sarkeshik A., Yates J.R., Fernandes M.J., McCollum D. Angiomotin family proteins are novel activators of the LATS2 kinase tumor suppressor. Mol. Biol. Cell 2011, 22:3725-3733.
79. Zhao B., Li L., Lu Q., Wang L.H., Liu C.-Y., Lei Q., Guan K.-L. Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein. Genes Dev. 2011, 25:51-63.
80. Voorhoeve P.M., le Sage C., Schrier M., Gillis A.J.M., Stoop H., Nagel R., Liu Y.-P., van Duijse J., Drost J., Griekspoor A., Zlotorynski E., Yabuta N., De Vita G., Nojima H., Looijenga L.H.J., Agami R. A genetic screen implicates miRNA-372 and miRNA-373 As oncogenes in testicular germ cell tumors. Cell 2006, 124:1169-1181.
81. Cho W., Shin J., Kim J., Lee M., Hong K., Lee J.-H., Koo K., Park J., Kim K.-S. miR-372 regulates cell cycle and apoptosis of ags human gastric cancer cell line through direct regulation of LATS2. Mol. Cells 2009, 28:521-527.
82. Lee K.-H., Goan Y.-G., Hsiao M., Lee C.-H., Jian S.-H., Lin J.-T., Chen Y.-L., Lu P.-J. MicroRNA-373 (miR-373) post-transcriptionally regulates large tumor suppressor, homolog 2 (LATS2) and stimulates proliferation in human esophageal cancer. Exp. Cell Res. 2009, 315:2529-2538.
83. Liu X., Sempere L.F., Ouyang H., Memoli V.A., Andrew A.S., Luo Y., Demidenko E., Korc M., Shi W., Preis M., Dragnev K.H., Li H., DiRenzo J., Bak M., Freemantle S.J., Kauppinen S., Dmitrovsky E. MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J. Clin. Investig. 2010, 120:1298-1309.
84. Zhang X., Milton C.C., Humbert P.O., Harvey K.F. Transcriptional output of the Salvador/warts/hippo pathway is controlled in distinct fashions in Drosophila melanogaster and mammalian cell lines. Cancer Res. 2009, 69:6033-6041.
85. Lapi E., Di Agostino S., Donzelli S., Gal H., Domany E., Rechavi G., Pandolfi P.P., Givol D., Strano S., Lu X., Blandino G. PML, YAP, and p73 are components of a proapoptotic autoregulatory feedback loop. Mol. Cell 2008, 32:803-814.
86. Zhang H., Wu S.N., Xing D. YAP accelerates A beta(25-35)-induced apoptosis through upregulation of Bax expression by interaction with p73. Apoptosis 2011, 16:808-821.
87. Kowalik M.A., Saliba C., Pibiri M., Perra A., Ledda-Columbano G.M., Sarotto I., Ghiso E., Giordano S., Columbano A. Yes-associated protein regulation of adaptive liver enlargement and hepatocellular carcinoma development in mice. Hepatology 2011, 53:2086-2096.
88. Xu M.Z., Yao T.J., Lee N.P.Y., Ng I.O.L., Chan Y.T., Zender L., Lowe S.W., Poon R.T.P., Luk J.M. Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer 2009, 115:4576-4585.
89. Zhang X., George J., Deb S., Degoutin J.L., Takano E.A., Fox S.B., Bowtell D.D., Harvey K.F. The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene. Oncogene 2011, 30:2810-2822.
90. Zhang L., Ye D.X., Pan H.Y., Wei K.J., Wang L.Z., Wang X.D., Shen G.F., Zhang Z.Y. Yes-associated protein promotes cell proliferation by activating Fos related activator-1 in oral squamous cell carcinoma. Oral Oncol. 2011, 47:693-697.
91. Hao Y.W., Chun A., Cheung K., Rashidi B., Yang X.L. Tumor suppressor LATS1 is a negative regulator of oncogene YAP. J. Biol. Chem. 2008, 283:5496-5509.
92. Zhao B., Li L., Tumaneng K., Wang C.Y., Guan K.L. A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). Genes Dev. 2010, 24:72-85.
93. Schlegelmilch K., Mohseni M., Kirak O., Pruszak J., Rodriguez J.R., Zhou D., Kreger B.T., Vasioukhin V., Avruch J., Brummelkamp T.R., Camargo F.D. Yap1 acts downstream of alpha-catenin to control epidermal proliferation. Cell 2011, 144:782-795.
94. Benjamin J.M., Nelson W.J. Bench to bedside and back again: molecular mechanisms of alpha-catenin function and roles in tumorigenesis. Semin. Cancer Biol. 2008, 18:53-64.
95. Chan S.W., Lim C.J., Chong Y.F., Pobbati A.V., Huang C., Hong W. Hippo pathway-independent restriction of TAZ and YAP by angiomotin. J. Biol. Chem. 2011, 286:7018-7026.
96. Oka T., Remue E., Meerschaert K., Vanloo B., Boucherie C., Gfeller D., Bader G.D., Sidhu S.S., Vandekerckhove J., Gettemans J., Sudol M. Functional complexes between YAP2 and ZO-2 are PDZ domain-dependent, and regulate YAP2 nuclear localization and signalling. Biochem. J. 2010, 432:461-472.
97. Oka T., Sudol M. Nuclear localization and pro-apoptotic signaling of YAP2 require intact PDZ-binding motif. Genes Cells 2009, 14:607-615.
98. Islas S., Vega J., Ponce L., Gonzalez-Mariscal L. Nuclear localization of the tight junction protein ZO-2 in epithelial cells. Exp. Cell Res. 2002, 274:138-148.
99. Tapia R., Huerta M., Islas S., Avila-Flores A., Lopez-Bayghen E., Weiske J., Huber O., Gonzalez-Mariscal L. Zona occludens-2 inhibits cyclin D1 expression and cell proliferation and exhibits changes in localization along the cell cycle. Mol. Biol. Cell 2009, 20:1102-1117.
100. Oka T., Schmitt A.P., Sudol M. Opposing roles of angiomotin-like-1 and zona occludens-2 on pro-apoptotic function of YAP. Oncogene 2012, 31:128-134.
101. Dupont S., Morsut L., Aragona M., Enzo E., Giulitti S., Cordenonsi M., Zanconato F., Le Digabel J., Forcato M., Bicciato S., Elvassore N., Piccolo S. Role of YAP/TAZ in mechanotransduction. Nature 2011, 474:179-183.
102. Wada K., Itoga K., Okano T., Yonemura S., Sasaki H. Hippo pathway regulation by cell morphology and stress fibers. Development 2011, 138:3907-3914.
103. Danovi S.A., Rossi M., Gudmundsdottir K., Yuan M., Melino G., Basu S. Yes-associated protein (YAP) is a critical mediator of c-Jun-dependent apoptosis. Cell Death Differ. 2008, 15:217-219.
104. Liu A.M., Poon R.T.P., Luk J.M. MicroRNA-375 targets Hippo-signaling effector YAP in liver cancer and inhibits tumor properties. Biochem. Biophys. Res. Commun. 2010, 394:623-627.
105. Nishikawa E., Osada H., Okazaki Y., Arima C., Tomida S., Tatematsu Y., Taguchi A., Shimada Y., Yanagisawa K., Yatabe Y., Toyokuni S., Sekido Y., Takahashi T. miR-375 is activated by ASH1 and inhibits YAP1 in a lineage-dependent manner in lung cancer. Cancer Res. 2011, 71:6165-6173.
106. Heallen T., Zhang M., Wang J., Bonilla-Claudio M., Klysik E., Johnson R.L., Martin J.F. Hippo pathway inhibits Wnt signaling to restrain cardiomyocyte proliferation and heart size. Science 2011, 332:458-461.
107. Ferrigno O., Lallemand F., Verrecchia F., L'Hoste S., Camonis J., Atfi A., Mauviel A. Yes-associated protein (YAP65) interacts with Smad7 and potentiates its inhibitory activity against TGF-beta/Smad signaling. Oncogene 2002, 21:4879-4884.
108. Alarcon C., Zaromytidou A.I., Xi Q., Gao S., Yu J., Fujisawa S., Barlas A., Miller A.N., Manova-Todorova K., Macias M.J., Sapkota G., Pan D., Massague J. Nuclear CDKs drive Smad transcriptional activation and turnover in BMP and TGF-beta pathways. Cell 2009, 139:757-769.
109. Varelas X., Samavarchi-Tehrani P., Narimatsu M., Weiss A., Cockburn K., Larsen B.G., Rossant J., Wrana J.L. The crumbs complex couples cell density sensing to hippo-dependent control of the TGF-beta-SMAD pathway. Dev. Cell 2010, 19:831-844.
110. Aragón E., Goerner N., Zaromytidou A.I., Xi Q., Escobedo A., Massagué J., Macias M.J. A Smad action turnover switch operated by WW domain readers of a phosphoserine code. Genes Dev. 2011, 25:1275-1288.
111. Cantor J.P., Iliopoulos D., Rao A.S., Druck T., Semba S., Han S.Y., McCorkell K.A., Lakshman T.V., Collins J.E., Wachsberger P., Friedberg J.S., Huebner K. Epigenetic modulation of endogenous tumor suppressor expression in lung cancer xenografts suppresses tumorigenicity. Int. J. Cancer 2007, 120:24-31.
112. Lee W., Jiang Z., Liu J., Haverty P.M., Guan Y., Stinson J., Yue P., Zhang Y., Pant K.P., Bhatt D., Ha C., Johnson S., Kennemer M.I., Mohan S., Nazarenko I., Watanabe C., Sparks A.B., Shames D.S., Gentleman R., de Sauvage F.J., Stern H., Pandita A., Ballinger D.G., Drmanac R., Modrusan Z., Seshagiri S., Zhang Z. The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature 2010, 465:473-477.
113. Wong K.M., Hudson T.J., McPherson J.D. Unraveling the genetics of cancer: genome sequencing and beyond. Annu. Rev. Genomics Hum. Genet. 2011, 12:407-430.